Does NMN lower blood sugar?

NMN improves insulin sensitivity — how effectively cells respond to insulin — rather than directly lowering blood glucose. Better insulin sensitivity means glucose is more efficiently moved from the bloodstream into cells, which can reduce fasting glucose levels over time. A 2024 trial in adults with metabolic syndrome also found modest fasting glucose reduction.

NAD+ glucose

NMN for Pre-Diabetes and Type 2 Diabetes Risk: The Insulin Sensitivity Evidence

Q: Can NMN help with pre-diabetes?

The landmark Yoshino et al. trial (Cell Metabolism, 2021) was conducted specifically in postmenopausal women with pre-diabetes and found NMN at 250mg daily for 10 weeks significantly improved skeletal muscle insulin sensitivity. This is the most directly applicable human NMN evidence for people with pre-diabetes, though it does not prove NMN prevents diabetes progression.

Q: Can NMN replace diabetes medication?

No. NMN addresses one cellular mechanism (NAD+-mediated insulin sensitivity in muscle). Diabetes is a multifactorial condition requiring medical management. NMN may be complementary to lifestyle modification and medication management, but it does not replace prescribed treatment. Discuss with your GP or endocrinologist.

June 4, 2026 · Nadovia Research Team

NMN pre-diabetes insulin sensitivity supplement Australia

Metabolic Health Guide · Updated June 2026

The most directly applicable published NMN human trial is also the one most relevant to Australians with pre-diabetes or type 2 diabetes risk. The Yoshino et al. trial (Cell Metabolism, 2021) was not conducted in generally healthy adults — it was conducted in postmenopausal women with pre-diabetes. Its primary finding: NMN at 250mg daily for 10 weeks significantly improved skeletal muscle insulin sensitivity.

Australia has approximately 2.5 million people with pre-diabetes and over 1.5 million with diagnosed Type 2 diabetes, according to the Australian Department of Health. For this population, the Yoshino finding is the most clinically specific NMN evidence available.

The Mechanism: Why NAD+ Matters for Insulin Sensitivity

Insulin sensitivity — how effectively your muscle cells take up glucose in response to insulin — depends on a series of NAD+-dependent cellular processes:

SIRT1 activation: SIRT1 improves insulin signalling in muscle cells by deacetylating key proteins in the insulin receptor pathway. Lower NAD+ → lower SIRT1 activity → impaired insulin signalling
Mitochondrial efficiency: Muscle glucose uptake for energy requires functional mitochondria. NAD+-depleted mitochondria are less efficient, reducing the energetic drive for glucose uptake
AMPK activation: AMPK — activated by exercise and also by adequate NAD+ — promotes GLUT4 translocation, the glucose transporter that moves glucose into muscle cells. NAD+ supports AMPK-mediated glucose uptake

The Yoshino Trial: The Evidence

Population: Postmenopausal women with pre-diabetes (impaired glucose tolerance)
Intervention: 250mg NMN daily for 10 weeks
Primary outcome: Skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp — the gold standard method)
Result: Significant improvement in muscle insulin sensitivity in the NMN group compared to placebo

This is a methodologically rigorous finding. The clamp method is considered more accurate than simpler glucose tolerance tests. The population — women with pre-diabetes — is one of the highest-risk groups for diabetes progression. The result is directly applicable to the question of whether NMN might slow pre-diabetes progression.

What this finding does not prove: NMN did not demonstrate reduction in diabetes progression rates in this trial — it was too short (10 weeks) and not designed to measure that endpoint. The insulin sensitivity improvement is mechanistically consistent with potential diabetes risk reduction, but that conclusion requires longer trials that have not been conducted.

2024 Extended Evidence: Metabolic Syndrome

A 2024 trial extended the Yoshino metabolic finding to a broader population: adults with metabolic syndrome (a cluster of risk factors including abdominal obesity, high blood glucose, high blood pressure, and dyslipidaemia). Key findings over 16 weeks:

Reduced fasting glucose levels in the NMN group vs placebo
Improved insulin sensitivity markers
Modest reduction in systolic blood pressure
No significant adverse effects

Important Safety Considerations for Australians with Diabetes

Consult your GP before starting NMN if you manage blood glucose:

NMN improves insulin sensitivity — if you are on medications that lower blood glucose (metformin, GLP-1 agonists, SGLT-2 inhibitors, insulin), combined effects could produce hypoglycaemia
Monitor blood glucose when starting NMN alongside diabetes management
NMN does not replace any prescribed medication for diabetes or pre-diabetes management
Diabetes Australia and your treating GP are the appropriate resources for diabetes management guidance

FAQ

Can NMN help with pre-diabetes?",

The Yoshino et al. trial found NMN significantly improved muscle insulin sensitivity in postmenopausal women with pre-diabetes. This is the most directly applicable human evidence for this population. NMN does not prove to prevent diabetes progression in human trials — longer studies are needed for that conclusion.

Is NMN safe for people with diabetes?",

NMN has an established safety profile in healthy adults. For diagnosed Type 2 diabetes on glucose-lowering medications, consult your GP — improved insulin sensitivity from NMN could interact with medication effects. Blood glucose monitoring is advisable when starting NMN alongside diabetes management.

Can NMN replace diabetes medication?",

No. NMN addresses one cellular mechanism in a multifactorial condition. It may be complementary to lifestyle and medication management — but it does not replace prescribed treatment. Discuss with your GP or endocrinologist.

The insulin sensitivity evidence — in the population it was studied in.

Nadovia Longevity Complex — 500mg NMN with the complete formula. Free AU shipping over $75.

View Longevity Complex →

References: Yoshino M et al., Cell Metabolism (2021); 2024 metabolic syndrome trial; AIHW diabetes statistics Australia; health.gov.au. Not medical advice — consult your GP for diabetes management.